CN104470532A - SorCS1在治疗肥胖症及超重中的应用 - Google Patents

SorCS1在治疗肥胖症及超重中的应用 Download PDF

Info

Publication number
CN104470532A
CN104470532A CN201380032064.3A CN201380032064A CN104470532A CN 104470532 A CN104470532 A CN 104470532A CN 201380032064 A CN201380032064 A CN 201380032064A CN 104470532 A CN104470532 A CN 104470532A
Authority
CN
China
Prior art keywords
amino acid
acid residues
seq
polypeptide
continuous amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380032064.3A
Other languages
English (en)
Chinese (zh)
Inventor
K-M·彼泽森
A·尼克尔
M·F·科尔比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of CN104470532A publication Critical patent/CN104470532A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380032064.3A 2012-04-17 2013-04-17 SorCS1在治疗肥胖症及超重中的应用 Pending CN104470532A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270191 2012-04-17
DKPA201270191 2012-04-17
PCT/DK2013/050107 WO2013156031A2 (fr) 2012-04-17 2013-04-17 Sorcs1 utilisable dans le traitement de l'obésité ou de la surcharge pondérale

Publications (1)

Publication Number Publication Date
CN104470532A true CN104470532A (zh) 2015-03-25

Family

ID=49384162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380032064.3A Pending CN104470532A (zh) 2012-04-17 2013-04-17 SorCS1在治疗肥胖症及超重中的应用

Country Status (10)

Country Link
US (1) US20150166629A1 (fr)
EP (1) EP2874646A4 (fr)
JP (1) JP2015514726A (fr)
CN (1) CN104470532A (fr)
AU (1) AU2013248727A1 (fr)
CA (1) CA2870211A1 (fr)
HK (1) HK1208159A1 (fr)
IL (1) IL235066A0 (fr)
SG (1) SG11201406455YA (fr)
WO (1) WO2013156031A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105136781A (zh) * 2015-08-13 2015-12-09 上海交通大学医学院附属瑞金医院 脂肪因子grem2在制备肥胖症治疗药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3666281A1 (fr) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprenant sortilin-1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022719A2 (fr) * 2002-09-09 2004-03-18 Wisconsin Alumni Research Foundation Genes de predisposition au diabete de type 2
WO2010142296A1 (fr) * 2009-06-10 2010-12-16 Aarhus Universitet Agent de type sor cs1 pour une utilisation dans le traitement d'une résistance à l'insuline et de maladies apparentées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
HUP0203751A3 (en) * 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
SI3225251T1 (sl) * 2006-12-21 2020-03-31 H. Lundbeck A/S Modulacija aktivnosti pronevrotrofinov
EP2008666A1 (fr) * 2007-06-29 2008-12-31 Institut Pasteur Utilisation d'anticorps VHH pour la préparation de vecteurs de peptide pour fournir une substance d'intérêt et leurs applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022719A2 (fr) * 2002-09-09 2004-03-18 Wisconsin Alumni Research Foundation Genes de predisposition au diabete de type 2
WO2010142296A1 (fr) * 2009-06-10 2010-12-16 Aarhus Universitet Agent de type sor cs1 pour une utilisation dans le traitement d'une résistance à l'insuline et de maladies apparentées

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105136781A (zh) * 2015-08-13 2015-12-09 上海交通大学医学院附属瑞金医院 脂肪因子grem2在制备肥胖症治疗药物中的应用
CN105136781B (zh) * 2015-08-13 2018-03-30 上海交通大学医学院附属瑞金医院 脂肪因子grem2作为药物靶点在治疗肥胖症药物中的应用

Also Published As

Publication number Publication date
WO2013156031A3 (fr) 2013-12-12
JP2015514726A (ja) 2015-05-21
HK1208159A1 (en) 2016-02-26
US20150166629A1 (en) 2015-06-18
EP2874646A2 (fr) 2015-05-27
CA2870211A1 (fr) 2013-10-24
SG11201406455YA (en) 2014-11-27
AU2013248727A1 (en) 2014-11-06
EP2874646A4 (fr) 2016-07-06
WO2013156031A2 (fr) 2013-10-24
IL235066A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
CN110229238B (zh) 人成纤维细胞生长因子21融合蛋白及其制备方法与用途
CN101443358B (zh) 生长素释放肽剪接变体在治疗恶病质和/或压食和/或厌食-恶病质和/或营养不良和/或脂肪营养障碍和/或肌肉消耗和/或刺激食欲中的用途
JP5918909B2 (ja) 標的化治療薬
TWI694085B (zh) 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
KR101459789B1 (ko) 안정화된 인슐린-유사 성장 인자 폴리펩티드
TWI471137B (zh) Ｃ型利鈉胜肽變異體
Hershkovitz et al. In vitro and in vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone
CN101123991B (zh) 胰岛素样生长因子-1（igf-i）和聚乙二醇的缀合物
JP6040464B2 (ja) 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
CN101189335B (zh) 瘦素拮抗剂
TW200927758A (en) Variants of C-type natriuretic peptide
JP2017101074A (ja) ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
CN101534846A (zh) 显示生理学溶解性和稳定性的胰高血糖素类似物
CN101578102A (zh) 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
CN102711733A (zh) 瞬时连接于聚合物载体的干生长激素组合物
CN106573072A (zh) 降低血清胆固醇的方法
CN102647995B (zh) 用于治疗胰岛素抵抗及与之相关的疾病的SorCS1样药剂
CN105658232A (zh) 使用白细胞介素-10治疗疾病和病症的方法
CN104994867A (zh) 作为用于口服药物递送的载体的原生动物变体特异性表面蛋白(vsp)
CN102292349A (zh) 稳定的生长激素化合物
ES2841123T3 (es) Formulación del compuesto de la hormona de crecimiento
CN104470532A (zh) SorCS1在治疗肥胖症及超重中的应用
TW201842929A (zh) 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
KR20160091888A (ko) 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체
US9637531B2 (en) Selective cartilage therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150325